Paper Details

  1. Home
  2. Paper Details

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.

Author: DuPontHerbert L, DuPontMargaret W, EricssonCharles D, JiangZhi-Dong, KeShi, Martinez-SandovalFrancisco, OkhuysenPablo C, de la CabadaFrancisco Javier

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Rifaximin, a nonabsorbable antibiotic, was effective in preventing travelers’ diarrhea in Mexico. It provided 72% protection against travelers’ diarrhea and 77% protection against antibiotic-treated travelers’ diarrhea.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Travelers' diarrhea causes substantial morbidity and postinfectious irritable bowel syndrome. OBJECTIVE: To evaluate nonabsorbable rifaximin for prevention of travelers' diarrhea. DESIGN: Randomized, double-blind, placebo-controlled clinical trial. SETTING: Guadalajara, Mexico. PARTI...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/0003-4819-142-10-200505170-00005

データ提供：米国国立医学図書館（NLM）

Rifaximin for Travelers' Diarrhea: A New Oasis in the Desert of Gastrointestinal Illnesses

Travelers' diarrhea is a common and often unpleasant ailment that can significantly impact the enjoyment of travel. This study investigates the effectiveness of rifaximin, a non-absorbable antibiotic, in preventing travelers' diarrhea. The study employs a randomized, double-blind, placebo-controlled design to compare the efficacy of rifaximin to placebo.

A Promising Solution: Rifaximin for Travelers' Diarrhea

The study demonstrates that rifaximin is effective in preventing travelers' diarrhea, significantly reducing the incidence of both diarrhea and antibiotic-treated diarrhea. The study also finds that rifaximin was well-tolerated, with minimal side effects. These findings provide strong evidence for the use of rifaximin as a prophylactic measure against travelers' diarrhea.

Protecting Travelers: A Journey to Safe and Enjoyable Travel

This study provides a valuable tool for travelers seeking to minimize the risk of developing travelers' diarrhea. The findings highlight the importance of preventive measures to ensure a safe and enjoyable travel experience. The study underscores the need for continued research and development of effective interventions to address this common travel ailment.

Dr. Camel's Conclusion

This study is a welcome oasis in the desert of gastrointestinal illnesses, offering travelers a safe and effective way to prevent travelers' diarrhea. The findings highlight the importance of preventative measures and emphasize the need for continued research and development of effective interventions for this common travel ailment. Just as a camel adapts to the challenges of a desert environment, travelers can now navigate the world with greater confidence, knowing that rifaximin can help protect them from the discomfort of travelers' diarrhea.
Date :
  1. Date Completed 2005-05-26
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

15897530

DOI: Digital Object Identifier

10.7326/0003-4819-142-10-200505170-00005

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.